Article · Wikipedia archive · Last revised Jul 13, 2026

M2613

M2613 is a nonsteroidal estrogen derived from triphenylbromoethylene which was studied for the treatment of breast cancer in women in the 1940s, but was never marketed.

Last revised
Jul 13, 2026
Read time
≈ 1 min
Length
167 w
Citations
3
Source
Wikipedia ↗
M2613
Clinical data
Other namesM-2613; Methoxyethoxy-triphenylbromoethylene
Drug classNonsteroidal estrogen
Identifiers
  • 1-Bromo-2-(p-ethoxyphenyl)-2-(p-methoxyphenyl)-1-phenylethylene
CAS Number
Chemical and physical data
FormulaC23H21BrO2
Molar mass409.323 g·mol−1
3D model (JSmol)
  • c1ccccc1C(Br)=C(c1ccc(OC)cc1)c1ccc(OCC)cc1
  • InChI=InChI=1S/C23H21BrO2/c1-3-26-21-15-11-18(12-16-21)22(17-9-13-20(25-2)14-10-17)23(24)19-7-5-4-6-8-19/h4-16H,3H2,1-2H3
  • Key:SPHDSWQIYGZLBR-UHFFFAOYSA-N

M2613 is a nonsteroidal estrogen derived from triphenylbromoethylene which was studied for the treatment of breast cancer in women in the 1940s, but was never marketed.12

Chemistry

Synthesis

The chemical synthesis of M2613 has been described:3

source ↗

The Grignard reaction between 1-(4-Ethoxyphenyl)-2-phenylethanone [38495-73-7] (1) and 4-Bromoanisole [104-92-7] (2) gives 3. Condensation with molecular bromine in the presence of glacial acetic acid completes the synthesis of M2613 (4). Alternately, Grignard reaction between 4-Ethoxy-4'-methoxybenzophenone [52886-92-7] (4) and benzyl bromide [100-39-0] (5) also yields 3.

See also

See also

References

References

  1. Walpole AL, Paterson E (October 1949). "Synthetic oestrogens in mammary cancer". Lancet. 2 (6583): 783–6. doi:10.1016/s0140-6736(49)91370-7. PMID 15391512.
  2. Jordan VC (February 2015). "The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer". Endocr. Relat. Cancer. 22 (1): R1–31. doi:10.1530/ERC-14-0448. PMC 4494663. PMID 25339261.
  3. Frederick Robert Basford, GB566415 (1944 to Imperial Chemical Industries Ltd).